Healthcare Jul 28, 2021 09:22 AM (GMT+8) · EqualOcean
Yiouda health learned on the 28th that recently, zanrong pharmaceutical announced that it had completed the round B financing of US $40 million, which was led by the world-famous investment institution OrbiMed (orbo capital), and the original shareholders Qiming venture capital, Sherpa investment, juming venture capital and power capital continued to follow. The current round of financing funds will be used for clinical research, preclinical research and talent introduction of continuous independent development projects. Founded in 2018, zanrong pharmaceutical is a biopharmaceutical enterprise that independently develops and innovates small molecule antitumor drugs from the perspective of DMPK. Based on the differential improvement of pharmacokinetics (DMPK), zonrong has laid out several anti-tumor pipelines, of which the newly developed innovative medicine for breast cancer brain metastasis has completed the clinical phase one climbing test in China and the United States. In addition, it also plans to promote another heavy source innovative new drug to enter the phase I clinical trial in China and the United States this year, and is expected to launch two PCCS (preclinical candidate drugs) at the beginning of next year to enter the preparation stage of ind package. In the follow-up, there are more new projects of DMPK differentiation or source innovation under active research and development.

This text is a result of machine translation.